Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2021-09-23 00:00:00 ET · period of report 2021-09-21 · accession 0001209191-21-057475 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-23 | 2021-09-21 | NTLA | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $149.81 | -2,400 | 791 | -75% | -$359.5K |
| D | 2021-09-23 | 2021-09-21 | NTLA | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +2,400 | 3,191 | +303% | +$30.3K |
| D | 2021-09-23 | 2021-09-21 | NTLA | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $0.00 | -2,400 | 192.8K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-21 | S | D | 2,400 | $149.81 | 791 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-21 | M | A | 2,400 | $12.62 | 3,191 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2021-09-21 | M | D | 2,400 | $0.00 | 192,800 | D | $12.62 · — to 2030-04-30 | 2,400 Common Stock | (F2) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,666 shares as of September 21, 2021. |